Pharmaceuticals

Incretin-Based Drugs Market Insights Report: Opportunities and Drivers 2030

February 16, 2026March 11, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the incretin-based drugs market from 2026–2035 with trusted insights from The Business Research Company

Across 2026–2030, what is the expected market valuation path of the Incretin-Based Drugs Market?

The incretin-based drugs market has witnessed significant expansion in recent years. Its value is anticipated to rise from $27.83 billion in 2025 to $29.88 billion in 2026, at a compound annual growth rate (CAGR) of 7.4%. This historical growth can be linked to factors such as the increasing prevalence of type 2 diabetes, higher rates of insulin resistance, the rise in lifestyle-related metabolic disorders, broader adoption of endocrinology drugs, and various hospital diabetes programs.

The incretin-based drugs market is projected for robust expansion in the coming years. It is anticipated to reach $39.25 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.1%. This projected growth during the forecast period stems from factors such as the global obesity epidemic, rising demand for weight management drugs, advancements in long-acting incretin formulations, the emphasis on personalized diabetes care, and a greater focus on preventive metabolic health. Key trends anticipated over this period encompass the swift uptake of GLP-1 receptor agonists, the broadening of indications for obesity management, an increased prevalence of oral incretin therapies, the development of more combination therapy strategies, and enhanced patient adherence facilitated by weekly dosing regimens.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24570&type=smp

Which Drivers Are Supporting The Rise Of The Incretin-Based Drugs Market?

The incretin-based drugs market is anticipated to expand due to the increasing occurrence of type 2 diabetes mellitus. This chronic metabolic condition is marked by insulin resistance and reduced insulin secretion, resulting in high blood glucose. Poor diet and lack of physical activity contribute to insulin resistance, making it harder for the body to manage blood sugar levels. Incretin-based drugs address type 2 diabetes by enhancing insulin secretion after meals and decreasing glucagon production, thereby lowering blood sugar. They also slow gastric emptying and suppress appetite, which assists in blood glucose management and weight loss. For example, in June 2024, the National Health Service reported that in 2023, approximately 549,000 additional individuals in England faced a risk of developing type 2 diabetes, pushing the total number with pre-diabetes to over 3.6 million, an increase of nearly 20% compared to 2022. Consequently, the growing incidence of type 2 diabetes mellitus is a key factor propelling the incretin-based drugs market.

What Leading Segments Are Studied In The Incretin-Based Drugs Market?

The incretin-based drugs market covered in this report is segmented –

1) By Type: Glucagon-Like Peptide-1 Receptor (GLP-1) Agonists, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors

2) By Route Of Administration: Oral, Injectable

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By Application: Type 2 Diabetes, Obesity, Other Applications

Subsegments:

1) By Glucagon-Like Peptide-1 Receptor (GLP-1) Agonists: Exenatide, Liraglutide, Dulaglutide, Semaglutide, Lixisenatide

2) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin, Vildagliptin

What Trends Are Driving The Growth Trajectory Of The Incretin-Based Drugs Market?

Companies operating significantly within the incretin-based drugs market are prioritizing the development of generic drug alternatives to provide more effective and convenient treatment choices for individuals with type 2 diabetes. A generic medication is characterized by possessing identical active ingredients, strength, dosage form, and administration route as its brand-name counterpart, yet it is marketed under its chemical designation without any brand labeling. For instance, in December 2024, Hikma Pharmaceuticals PLC, a pharmaceutical firm based in the UK, introduced the initial generic version of Victoza (liraglutide) injection, 6 mg/mL, in the United States. This product secured approval from the Food and Drug Administration (FDA). It is prescribed as an addition to diet and exercise for enhancing glycemic control in adults and pediatric patients aged 10 years and older diagnosed with type 2 diabetes, thereby offering a fresh, more economical solution amidst current scarcities of GLP-1 medications.

Which Major Firms Are Strengthening Their Position In The Incretin-Based Drugs Market?

Major companies operating in the incretin-based drugs market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Amgen Inc., Novo Nordisk A/S, Viatris, Boehringer Ingelheim GmbH, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Sumitomo Dainippon Pharma Co. Ltd., Hikma Pharmaceuticals PLC, Lupin Limited, Mitsubishi Tanabe Pharma Corporation

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/incretin-based-drugs-global-market-report

Which Region Shows The Strongest Potential For Future Expansion In The Incretin-Based Drugs Market?

North America was the largest region in the incretin-based drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the incretin-based drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Incretin-Based Drugs Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24570&type=smp

Browse Through More Reports Similar to the Global Incretin-Based Drugs Market 2026, By The Business Research Company

Pharmaceutical Drug Delivery Market Report 2026

https://www.thebusinessresearchcompany.com/report/pharmaceutical-drug-delivery-global-market-report

Drug Formulation Market Report 2026

https://www.thebusinessresearchcompany.com/report/drug-formulation-global-market-report

Pharmaceuticals Market Report 2026

https://www.thebusinessresearchcompany.com/report/pharmaceuticals-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795